Sales funnels and closing techniques.
Most B2B prospecting misses because reps pitch instead of teach. Here's a field-based approach using insight-led outreach and proactive follow-up that...
Most B2B deals don't lose to a competitor—they die at 'no decision.' Learn to take control, teach your buyer, and close more.
Most reps treat every objection as a price problem. But the real killer is often hidden risk. Here's how to dig it out with a few practical tactics—an...
Most objection training teaches you to defend against 'no'. I'll show you why the Challenger approach—teaching, tailoring, taking control—beats Sandle...
Cold outreach is often dismissed as spam, but research shows proactive prospecting wins. Here's why you should embrace it, and how to do it right.
BANT is a 1950s relic for transactional sales; MEDDIC wins for complex B2B deals. My head-to-head comparison shows when to use each — and why MEDDIC's...
Imagine you're drowning in leads. Most aren't qualified. Use BANT to filter. Here's how to apply it step by step.
Sandler, Challenger, and MEDDICC each promise better B2B negotiation outcomes. Here's a blunt comparison across four criteria—and when each one wins.
In B2B prospecting, buyers don't want more pitches—they want insight. Here's how to turn your prospecting into a teaching moment that wins meetings.
Almost 80% of B2B deals are lost to no decision, not to a competitor. Learn how to teach buyers something new, take control of the process, and close ...
Challenger reps win by teaching, not befriending. Here's how to apply the research to your next deal and close more.
I used to ask about budget first. It cost me a deal that would've paid my rent for a year. Here's how MEDDIC and SPIN actually qualify deals, and why ...